Test strategies for the detection of myocardial damage.
In the space of half a century, cardiac marker testing has advanced incrementally from enzymes present in nearly all tissues to proteins having remarkable specificity for myocardium. Markers with other desirable properties, such as earlier release, have also been introduced and others may be anticipated, although a single perfect marker is not on the horizon. Optimum application of these new markers still requires improved robustness and harmonization of commercial assays, and continuing insights in the pathophysiology of acute coronary syndromes. As these advances occur, future testing will likely focus more on therapeutic decisions than on arbitrary diagnostic classifications.
Department of Pathology, University Hospital and Medical Center, Stony Brook University, Stony Brook, NY 11794-7300, USA. jbock@notes.cc.sunysb.edu
Jay L
JL
Bock
D015415:Biomarkers / Q000097:blood; D009202:Cardiomyopathies / Q000097:blood / Q000175:diagnosis*; D003327:Coronary Disease / Q000097:blood / Q000175:diagnosis; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis; D010338:Pathology, Clinical / Q000379:methods*
D015415:Biomarkers